CellaVision receives CE marking

Amferia's antibacterial wound dressing has been granted approval by the US Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the US market with a unique Class 2 medical device antibacterial dressing for advanced wound care.

Devyser Diagnostics has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB, a Swedish company within the Level Bio group.

On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.

Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.

The two companies have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.

The Board of Directors of Episurf Medical has entered into an agreement with Goldcup 38657 AB regarding the acquisition of all shares in Goldcup 38658 AB, a wholly owned subsidiary of the seller.

The program is targeting annualised savings of SEK 65 million, expected to have a positive impact in the first half of 2026, and to reach full effect by the end of the third quarter 2026.